Search the Newsreel

iRhythm Holdings Announces Second Quarter 2026 Financial Results

iRhythm SAN FRANCISCO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- iRhythm Holdings, Inc. (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended June 30, 2026. Second …

iRhythm earnings up next: Narrowing losses in focus tonight

iRhythm Technologies Inc. is scheduled to report second-quarter earnings, with analysts expecting a narrower loss of 5 cents per share and revenue of $219.3 million, indicating substantial improvement from the previous quarter. Investors will be focused on the company's ability to maintain rapid growth …

Bernstein Litowitz Berger & Grossmann LLP Announces Proposed Class Action Settlement on Behalf of Purchasers of iRhythm Technologies, Inc. Common Stock

Bernstein Litowitz Berger & Grossmann LLP announced a proposed class action settlement for purchasers of iRhythm Technologies, Inc. common stock. The $45,000,000 cash settlement aims to resolve claims alleging materially false and misleading statements regarding iRhythm's Zio AT heart monitoring device between July 25, …

Acrophyte Hospitality Trust Reports Earnings Results for the Half Year Ended June 30, 2026

iRhythm Technologies (NASDAQ:IRTC) Issues Quarterly Earnings Results

iRhythm Holdings, Inc. (IRTC) Tops Q2 Earnings and Revenue Estimates

Rhythm Pharmaceuticals (RYTM) Stock Rises As HO Demand Meets Loss Pressure

Rhythm Biosciences (ASX:RHY): ColoSTAT's Commercial Momentum Is Ramping Up Quickly In FY27!

Acrophyte Hospitality Trust Suspends Distributions from First Half of 2026

Rhythm Pharmaceuticals (NASDAQ:RYTM) Price Target Raised to $160.00

Citizens JMP raised its price target for Rhythm Pharmaceuticals (NASDAQ:RYTM) to $160.00 from $155.00, maintaining a "market outperform" rating and suggesting a 47.56% upside. The company reported strong Q3 revenue of $71.25 million, exceeding estimates, and beat EPS expectations. Analyst sentiment remains largely positive …

Rhythm Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:RYTM) 2026-08-05

Rhythm Pharmaceuticals, Inc. published its Q2 2026 earnings call presentation, detailing its financial results. The company reported an EPS of -$0.73, beating estimates by $0.10, and revenue of $71.26M, a 46.91% year-over-year increase, exceeding expectations by $3.60M. This report was issued in conjunction with …

Citigroup Issues Positive Forecast for Rhythm Pharmaceuticals (NASDAQ:RYTM) Stock Price

RBC Adjusts Price Target on Rhythm Pharmaceuticals to $155 From $141, Maintains Outperform Rating

RBC Capital has increased its price target for Rhythm Pharmaceuticals (RYTM) to $155 from $141, while reiterating an Outperform rating on the stock. This adjustment follows Rhythm Pharmaceuticals' Q2 2026 earnings call and other recent news, including promising data for its drug in brain …

Full Transcript: Rhythm Pharmaceuticals Q2 2026 Earnings Call

Rhythm Pharmaceuticals reported strong Q2 2026 results with global net product sales of IMCIVREE at $71.3 million, a 19% sequential increase. The company highlighted a successful U.S. launch of IMCIVREE for acquired hypothalamic obesity, receiving over 400 start forms in 14 weeks. Promising preliminary …

RHYTHM PHARMACEUTICALS, INC. 2026: Revenue $71.26M, EPS ($0.73) — 10-Q Summary

RHYTHM PHARMACEUTICALS, INC. (RYTM) reported its 2026 results, showing revenue of $71.26 million, a 46.9% increase from the prior year. Despite the revenue growth, the company posted a net loss of $50.36 million and a diluted EPS of ($0.73). The growth was primarily driven …

Pyrophyte Acquisition Corp. II Revenue Breakdown – NYSE:PAII.U

Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences

Rhythm Pharmaceuticals, Inc. announced that its Chairman, President and Chief Executive Officer, David Meeker, M.D., and Chief Financial Officer, Hunter Smith, will participate in fireside chats at three upcoming investor conferences in August and September 2026. These presentations will be webcasted and available on …

Rhythm Pharmaceuticals (NASDAQ:RYTM) Issues Quarterly Earnings Results

Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q2 Loss, Tops Revenue Estimates

Rhythm Pharmaceuticals (RYTM) reported a Q2 loss of $0.73 per share, exceeding the Zacks Consensus Estimate of a $0.81 loss by 9.88%. The company also surpassed revenue estimates, posting $71.26 million against an expectation of $67.12 million. Despite outperforming earnings expectations in three of …

Earnings Flash (RYTM) Rhythm Pharmaceuticals, Inc. Reports Q2 Revenue $71.3M, vs. FactSet Est of $67.7M

Rhythm Pharmaceuticals, Inc. reported its Q2 2026 revenue at $71.3 million, surpassing the FactSet estimate of $67.7 million. The company's lead asset, IMCIVREE, is an MC4R agonist approved for treating hyperphagia and severe obesity in various genetic and acquired conditions. Rhythm Pharmaceuticals is also …

Rhythm Pharmaceuticals 2Q Rev $71.3M >RYTM

Rhythm Pharmaceuticals reported its second-quarter revenue of $71.3 million. This brief report provides a key financial update for the company.

Rhythm Pharmaceuticals GAAP EPS of -$0.73 beats by $0.09, revenue of $71.26M beats by $3.6M

* Rhythm Pharmaceuticals press release [https://seekingalpha.com/pr/20605381-rhythm-pharmaceuticals-reports-second-quarter-2026-financial-results-and-business-update] (RYTM [https://seekingalpha.com/symbol/RYTM]): Q2 GAAP EPS of -$0.73 beats by $0.09. * Revenue of $71.26M (+46.9% Y/Y) beats by $3.6M. * Net product revenues from global sales of IMCIVREE were $71.3 million for the second quarter of 2026, as …

Rhythm Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

Rhythm Pharmaceuticals reported strong second-quarter 2026 financial results, with global IMCIVREE sales reaching $71.3 million, a 19% sequential increase. The company highlighted a successful U.S. launch of IMCIVREE for acquired hypothalamic obesity (HO), with over 400 patient start forms, and positive clinical data for …

Rhythm Pharmaceuticals Announces Preliminary Data from Phase 2 Trial that Showed RM-718 Demonstrated Positive Efficacy Signal in Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals announced positive preliminary data from its Phase 2 trial of RM-718, an investigational once-weekly MC4R agonist, for acquired hypothalamic obesity (HO). The study showed an 11.6% mean reduction in BMI from baseline at Week 16, consistent with previous treatments like setmelanotide and …

After FDA approval, Rhythm's IMCIVREE logs more than 400 U.S. start forms

Rhythm Pharmaceuticals announced strong Q2 2026 financial results, with net product revenue from global IMCIVREE sales reaching $71.3 million, a 19% sequential increase. The growth was largely driven by the U.S. launch of IMCIVREE for acquired hypothalamic obesity (HO), which generated over 400 patient …

iRhythm (IRTC) To Report Earnings Tomorrow: Here Is What To Expect

Rhythm Pharmaceuticals, Inc. (RYTM) Stock Analysis: A Look at Strong Analyst Ratings and Significant Growth Potential

Rhythm Pharmaceuticals (RYTM) is gaining investor attention due to its promising drug pipeline for rare neuroendocrine diseases and strong analyst endorsements. Despite current unprofitability and a slight stock price dip, its significant revenue growth and high average target price suggest substantial growth potential. Investors …

Algorhythm Holdings (NASDAQ: RIME) Among EZRA, RITR, HYFM, as SemiCab Expands Globally

Algorhythm Holdings (NASDAQ: RIME) is experiencing significant growth with its SemiCab platform, expanding globally and accelerating revenue. The company secured new enterprise customers like Coca-Cola India and Onida Electronics, while strengthening financial standing with a $9.5 million capital infusion and a $12 million annualized …

Rhythm Pharmaceuticals in spotlight: earnings test for HO launch By Investing.com

Rhythm Pharmaceuticals (RYTM) is under investor scrutiny as it prepares to release its Q2 earnings, which will provide the first detailed look at revenue from its newly approved treatment for acquired hypothalamic obesity (HO). Analysts are bullish, expecting an 81-cent loss per share on …

iRhythm Technologies $45M Securities Class Action Settlement

iRhythm Technologies and its CEO have agreed to a $45 million securities class action settlement. Investors who purchased the company's common stock between July 25, 2022, and August 9, 2024, may be eligible to claim a cash payment. The lawsuit alleged false and misleading …

Rhythm Pharmaceuticals (RYTM) Stock Looks Above Fair Value But Sales Stay Strong

Rhythm Pharmaceuticals (RYTM) has seen substantial stock growth over the past five years, but its current valuation suggests it is now overvalued, trading at a P/S ratio of 31.3x compared to an industry average of 10.5x and a fair P/S of 19.8x. While strong …

(RYTM) Volatility Zones as Tactical Triggers

Rhythm Pharmaceuticals Inc. (NASDAQ: RYTM) is showing divergent sentiment across horizons, indicating choppy conditions. AI models have generated three distinct trading strategies: a Position Trading Strategy, a Momentum Breakout Strategy, and a Risk Hedging Strategy, each with specific entry, target, and stop loss levels. …

Rhythm Pharmaceuticals, Inc. $RYTM Shares Sold by Janus Henderson Group PLC

Rhythm Pharmaceuticals, Inc. Revenue Breakdown – NASDAQ:RYTM

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) generated a total revenue of $194.77 million USD last year. The majority of this revenue, $189.76 million USD, came from its Therapeutics segment. The United States was the largest geographical contributor, accounting for $133.55 million USD of the revenue.

iRhythm Technologies Inc (IRTC) Institutional Confidence

The article provides an analysis of iRhythm Technologies Inc's (IRTC) institutional confidence, noting its current score of 10.00, which ranks 1st in its industry. It details that the institutional shareholding proportion is 107.08%, with a slight decrease quarter-over-quarter. The largest institutional shareholder is Steven …

Rhythm Pharmaceuticals Inc (RYTM) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Rhythm Pharmaceuticals Inc (RYTM), detailing its current price momentum, support and resistance levels, and various technical indicator readings. It shows that RYTM's stock price is currently trading between resistance at $114.09 and support at $99.21, suggesting suitability …